AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy rating, reflecting confidence in the company's growth and cash flow improvements. The company forecasts fiscal 2027 sales between $336 million and $341 million, with the stock hitting a 52-week high of $14.80, signaling strong market optimism.
In Austria, selling Bitcoin directly between private individuals is taxed the same as sales via crypto exchanges. The taxable event is the capital gain—the difference between sale proceeds and acquisition cost—with a 27.5% tax rate for Bitcoin acquir...
The U.S. SEC has approved Evernorth's registration, clearing the way for its $1 billion Nasdaq listing under the ticker XRPN through a merger with Armada Acquisition Corp. II. Evernorth plans to actively manage its XRP treasury to generate yield and ...
Amprius Technologies is benefiting from strong demand for drone batteries, reporting a 125.7% year-over-year revenue increase and improved gross margins. The company raised its 2026 revenue forecast to at least $140 million and aims for $600 million ...
INmune Bio is considered significantly undervalued with its treatment Ebstrocel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) driving a strong investment case. Ebstrocel offers systemic itch reduction, setting it apart from competitors like K...
PayPal's stock dropped sharply by 14.67% to $52.45 after Stripe and Advent withdrew their $60.50 per share acquisition offer, causing the company's market value to fall from $52.58 billion to $44.87 billion. This reversal ended the summer rally drive...
